title: Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?
authors: Ahmet Emre
authors: AE
authors: Eskazan
authors: Teoman
authors: T
authors: Soysal
authors: Yucel
authors: Y
authors: Erbilgin
authors: Ugur
authors: U
authors: Ozbek
authors: Burhan
authors: B
authors: Ferhanoglu